Stratos Wealth Advisors LLC Acquires New Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Stratos Wealth Advisors LLC acquired a new position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 8,000 shares of the biopharmaceutical company's stock, valued at approximately $241,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in TGTX. State Street Corp boosted its stake in TG Therapeutics by 35.8% in the 3rd quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company's stock worth $212,712,000 after purchasing an additional 2,398,015 shares during the period. Principal Financial Group Inc. lifted its position in TG Therapeutics by 1,549.4% in the 3rd quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company's stock worth $18,061,000 after buying an additional 725,371 shares in the last quarter. Public Sector Pension Investment Board purchased a new stake in TG Therapeutics in the 3rd quarter worth approximately $6,619,000. JPMorgan Chase & Co. lifted its position in TG Therapeutics by 60.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company's stock worth $16,859,000 after buying an additional 270,286 shares in the last quarter. Finally, PFM Health Sciences LP purchased a new stake in TG Therapeutics in the 3rd quarter worth approximately $5,459,000. Institutional investors and hedge funds own 58.58% of the company's stock.

TG Therapeutics Price Performance

NASDAQ:TGTX traded down $0.21 on Wednesday, reaching $30.90. The stock had a trading volume of 1,461,039 shares, compared to its average volume of 2,332,903. TG Therapeutics, Inc. has a 1-year low of $12.84 and a 1-year high of $36.84. The company has a market capitalization of $4.81 billion, a P/E ratio of -308.97 and a beta of 2.26. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The stock has a fifty day moving average price of $31.33 and a 200-day moving average price of $27.18.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on TGTX shares. StockNews.com downgraded shares of TG Therapeutics from a "hold" rating to a "sell" rating in a research report on Friday, January 31st. TD Cowen assumed coverage on shares of TG Therapeutics in a research report on Tuesday, October 29th. They issued a "buy" rating and a $50.00 target price for the company. HC Wainwright restated a "buy" rating and set a $55.00 price target on shares of TG Therapeutics in a report on Wednesday, January 15th. JPMorgan Chase & Co. raised their price target on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an "overweight" rating in a report on Monday, November 25th. Finally, The Goldman Sachs Group lifted their target price on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a "neutral" rating in a report on Tuesday, November 5th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. According to data from MarketBeat, TG Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $40.67.

Insiders Place Their Bets

In related news, CFO Sean A. Power sold 10,021 shares of the business's stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $28.53, for a total transaction of $285,899.13. Following the completion of the sale, the chief financial officer now directly owns 660,611 shares of the company's stock, valued at $18,847,231.83. The trade was a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 10.50% of the company's stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.